Aegerion names Remi Menes new CCO
“Remi brings extensive pre-launch and launch expertise and a proven ability to develop and lead commercial efforts globally,” Aegerion CEO Mary Szela said. “Commercialization of rare disease therapies takes a targeted approach and requires strong patient focus. Remi’s broad experience implementing holistic, patient-centered programs that demonstrate the value proposition of therapies make him ideally suited to lead our commercial operations globally, including our sales, marketing and market access efforts. We look forward to his contributions as we continue to drive and evolve our global commercial operations, and particularly as we prepare to submit a marketing authorization application for MYALEPT in the EU by year-end and, upon anticipated marketing approval, launch JUXTAPID in Japan.”
Menes’ most recent experience came with AbbVie Finland, where he served as the General Manager. While there, he was responsible for its affiliate operations and P&L’s as well as its flagship product Humira. He served on the Board of Pharma Industry Finland. Prior to his work with AbbVie Finland he held the position of Area Commercial Director, Virology & Neonatal Care, Western Europe & Canada with AbbVie Europe.
Aegerion Pharmaceuticals focuses on the development and commercialization of innovative therapies for patients with debilitating rare diseases.